Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 20/20 | 0.62 |
| ▸ | FAP | Q12884 | 1/20 | 0.51 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.51 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16677118 | 1.00 | DPP4 (0.62) | DPP4FAPDPP8DPP9 | |
| SCHEMBL14417783 | 1.00 | DPP4 (0.62) | DPP4FAPDPP8DPP9 | |
| SCHEMBL1154649 | 1.00 | DPP4 (0.62) | DPP4FAPDPP8DPP9 | |
| SCHEMBL1397859 | 1.00 | DPP4 (0.62) | DPP4FAPDPP8DPP9 | |
| SCHEMBL3785926 | 1.00 | DPP4 (0.62) | DPP4FAPDPP8DPP9 | |
| SCHEMBL23360603 | 1.00 | DPP4 (0.62) | DPP4FAPDPP8DPP9 | |
| SCHEMBL1493788 | 0.85 | DPP4 (0.64) | DPP4FAPDPP8DPP9 | |
| SCHEMBL14417777 | 0.83 | DPP4 (0.65) | DPP4 | |
| SCHEMBL3828184 | 0.83 | DPP4 (0.62) | DPP4FAPDPP8DPP9 | |
| SCHEMBL14432101 | 0.83 | DPP4 (0.62) | DPP4FAPDPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4055014-B1 | PYRROLIDINE AND PIPERIDINE COMPOUNDS | YUHAN CORP (KR) | 2025-04-30 | — | — | EP | disclosed |
| CN-114867719-B | Pyrrolidine and piperidine compounds | 柳韩洋行 | 2024-06-25 | — | — | CN | disclosed |
| US-11655235-B2 | Pyrrolidine and piperidine compounds | YUHAN CORPORATION (KR) | 2023-05-23 | — | — | US | disclosed |
| EP-4055014-A1 | PYRROLIDINE AND PIPERIDINE COMPOUNDS | Yuhan Corporation (KR) | 2022-09-14 | — | — | EP | disclosed |
| CN-114867719-A | Pyrrolidine and piperidine compounds | 柳韩洋行 | 2022-08-05 | — | — | CN | disclosed |
| US-20210147386-A1 | PYRROLIDINE AND PIPERIDINE COMPOUNDS | YUHAN CORPORATION (KR) | 2021-05-20 | — | — | US | disclosed |
| EP-2376447-B1 | DIPEPTIDYL PEPTIDASE IV INHIBITORS | ORCHID PHARMA LTD (IN) | 2017-08-09 | — | — | EP | disclosed |
| EP-2865666-B1 | HEXAHYDROPENTALENO DERIVATIVES, PREPARATION METHOD AND USE IN MEDICINE THEREOF | SUNSHINE LAKE PHARMA CO LTD (CN) | 2017-05-31 | — | — | EP | disclosed |
| EP-2865666-B1 | HEXAHYDROPENTALENO DERIVATIVES, PREPARATION METHOD AND USE IN MEDICINE THEREOF | SUNSHINE LAKE PHARMA CO LTD (CN) | 2017-05-31 | — | — | EP | disclosed |
| US-9567300-B2 | Hexahydropentaleno derivatives, preparation method and use in medicine thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2017-02-14 | — | — | US | disclosed |
| WO-2006011035-A1 | NOVEL DIPEPTIDYL PEPTIDASE IV INHIBITORS; PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM | GLENMARK PHARMACEUTICALS LTD. (US) | 2006-02-02 | — | — | WO | disclosed |
| WO-2006011035-A1 | NOVEL DIPEPTIDYL PEPTIDASE IV INHIBITORS; PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM | GLENMARK PHARMACEUTICALS LTD. (US) | 2006-02-02 | — | — | WO | disclosed |
| US-20050261501-A1 | Pyrrolidine and thiazolidine compounds | LES LABORATOIRES SERVIER (FR) | 2005-11-24 | — | — | US | disclosed |
| US-20050192324-A1 | Novel dipeptidyl peptidase IV inhibitors; processes for their preparation and compositions thereof | GLENMARK PHARMACEUTICALS LTD. (IN) | 2005-09-01 | — | — | US | disclosed |
| WO-2005075426-A1 | NOVEL DIPEPTIDYL PEPTIDASE IV INHIBITORS; PROCESSES FOR THEIR PREPARATION AND COMPOSITIONS THEREOF | GLENMARK PHARMACEUTICALS LTD. (US) | 2005-08-18 | — | — | WO | disclosed |
| US-20050176771-A1 | 2-Cyano-4-fluoropyrrolidine derivative or its salt | ASTELLAS PHARMA INC. (JP) | 2005-08-11 | — | — | US | disclosed |
| US-20050137224-A1 | 2-Cyanopyrrolidinecarboxamide compound | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-06-23 | — | — | US | disclosed |
| US-20050130981-A1 | Compounds | SANOFI-AVENTIS (FR) | 2005-06-16 | — | — | US | disclosed |
| EP-1541551-A1 | 2-CYANO-4-FLUOROPYRROLIDINE DERIVATIVE OR ITS SALT | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2005-06-15 | — | — | EP | disclosed |
| WO-2005042533-A2 | 2-CYANOPYRROLIDINECARBOXAMIDES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS | ASTELLAS PHARMA INC. (JP) | 2005-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130981-A1 | Compounds | DPP4, DPP3, DPP7 | DPP4 1/4885FAP 12/4885DPP8 5/4885 |
| US-20050261501-A1 | Pyrrolidine and thiazolidine compounds | DPP4, DPP3, NR4A1 | DPP4 1/4885FAP 1928/4885DPP8 10/4885 |
| US-20050137224-A1 | 2-Cyanopyrrolidinecarboxamide compound | DPP4, DPP3, DPP7 | DPP4 1/4885FAP 64/4885DPP8 4/4885 |
| US-20050176771-A1 | 2-Cyano-4-fluoropyrrolidine derivative or its salt | DPP4, DPP7, DPP9 | DPP4 1/4885FAP 107/4885DPP8 4/4885 |
| US-11655235-B2 | Pyrrolidine and piperidine compounds | FAP, APC, VHL | DPP4 126/4885FAP 1/4885DPP8 211/4885 |
| US-20050192324-A1 | Novel dipeptidyl peptidase IV inhibitors; processes for their preparation and compositions thereof | DPP4, DPP3, DPP7 | DPP4 1/4885FAP 16/4885DPP8 5/4885 |
| US-20210147386-A1 | PYRROLIDINE AND PIPERIDINE COMPOUNDS | FAP, APC, VHL | DPP4 126/4885FAP 1/4885DPP8 211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.